ovarian cancer

by Linköping University edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Donatella Puglisi, associate professor at Linköping University. Credit: Olov Planthaber Using machine learning, an electronic nose can “smell” early signs of ovarian cancer in the blood. The method is precise and, according to the LiU researchers behind the study, […]

by CureLab Oncology edited by Gaby Clark, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection. In the reporting, researchers supplementing the standard of care (chemotherapy) with Elenagen, have significantly extended overall survival for patients with the deadliest

by Michele W Sequeira, University of New Mexico Cancer Center edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes Ovarian cancer cells with activated Notch3 are more sensitive to auranofin. A, Western blot analysis of total cell lysates showing Notch3 and RBPJ levels in seven established ovarian cancer cell lines. Histone H3 was used as a loading

by University of Texas at El Paso edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Fabian R. Villagomez, Ph.D., a postdoctoral researcher in the Department of Biological Sciences at The University of Texas at El Paso, is studying high-grade serous carcinoma, an aggressive form of ovarian cancer. His work has helped identify a new target, Claudin-4,

by RMIT University edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes Credit: CC0 Public Domain New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular treatment for ovarian cancer, known as PARP inhibitor therapy. The work appears in the journal Nature Communications. More than 300,000 women are diagnosed

by University of South Australia edited by Lisa Lock, reviewed by Robert Egan F2R protein expression in ovarian cancer tissues. Credit: International Journal of Molecular Sciences (2025). DOI: 10.3390/ijms26178529 Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly improve the outlook for women diagnosed with this aggressive disease. Ovarian cancer is the

by Michael Addelman, University of Manchester edited by Sadie Harley, reviewed by Andrew Zinin Credit: Karolina Grabowska from Pexels A new blood test pioneered by diagnostics company AOA Dx (AOA) can detect ovarian cancer in symptomatic women with high accuracy, a study by researchers from the Universities of Manchester and Colorado has found. The study assessed AOA’s novel technology that

by Linda Wang, University of California, Los Angeles edited by Lisa Lock, reviewed by Robert Egan Microscopy image showing allogeneic stem cell-derived CAR-NKT cells (blue) attacking a human ovarian cancer cell (magenta). Credit: Lili Yang Lab/UCLA Ovarian cancer is the leading cause of death among women with gynecological cancers. The current medical playbook—surgery followed by chemotherapy—initially shows promise.

by Weill Cornell Medical College edited by Sadie Harley, reviewed by Robert Egan Ovarian cancer cells dividing. Credit: ecancer A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The research reveals a promising strategy against this hard-to-treat malignancy, and more